Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 3/20 | 0.65 |
| ▸ | IGF1R | P08069 | 5/20 | 0.64 |
| ▸ | AURKA | O14965 | 4/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.58 |
| ▸ | PLK1 | P53350 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 6/20 | 0.55 |
| ▸ | JAK3 | P52333 | 3/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.55 |
| ▸ | CDK4 | P11802 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.51 |
| ▸ | CIT | O14578 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23887678 | 1.00 | PLK4 (0.65) | PLK4IGF1RAURKAAURKBPLK1 | |
| SCHEMBL25269921 | 0.92 | PLK4 (0.67) | PLK4IGF1RAURKAAURKBPLK1 | |
| SCHEMBL30086502 | 0.92 | PLK4 (0.67) | PLK4IGF1RAURKAAURKBPLK1 | |
| SCHEMBL30086696 | 0.91 | PLK4 (0.54) | PLK4IGF1RAURKAAURKBPLK1 | |
| SCHEMBL23906665 | 0.91 | PLK4 (0.54) | PLK4IGF1RAURKAAURKBPLK1 | |
| SCHEMBL23906886 | 0.90 | JAK2 (0.66) | PLK4IGF1RAURKAAURKBJAK2 | |
| SCHEMBL30086423 | 0.90 | JAK2 (0.66) | PLK4IGF1RAURKAAURKBJAK2 | |
| SCHEMBL30086476 | 0.89 | CDK4 (0.51) | PLK4IGF1RAURKAAURKBPLK1 | |
| SCHEMBL23906230 | 0.89 | CDK4 (0.51) | PLK4IGF1RAURKAAURKBPLK1 | |
| SCHEMBL23887589 | 0.89 | JAK2 (0.52) | PLK4IGF1RAURKAAURKBPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| EP-4126824-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | Theravance Biopharma R&D IP, LLC (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115443269-A | Substituted pyrimidines and methods of use | 施万生物制药研发IP有限责任公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | PLK4 1890/4885IGF1R 558/4885AURKA 905/4885 |
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | PLK4 1890/4885IGF1R 558/4885AURKA 905/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | PLK4 1890/4885IGF1R 558/4885AURKA 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.